Table 3.
Univariate and multivariate analyses of factors associated with overall survival
| Variables | Overall survival | Disease-free survival | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Univariate analyses | ||||
| Age (> 50 vs. ≤ 50) | 1.10 (0.63–1.91) | 0.734 | 1.18 (0.70–2.00) | 0.537 |
| Histological subtype (serous vs. non-serous) | 2.24 (1.12–4.47) | 0.023 | 2.29 (1.18–4.43) | 0.014 |
| FIGO stage (III/IV vs. I/II) | 7.89 (3.53–17.60) | < 0.0001 | 9.40 (4.23–20.86) | <0.0001 |
| Histological grade (G2/G3 vs. G1) | 1.36 (0.72, 2.54) | 0.341 | 1.44 (0.79–2.63) | 0.239 |
| Intravascular tumor thrombus (Yes vs. No) | 2.27 (1.20–4.29) | 0.012 | 2.00 (1.07–3.75) | 0.030 |
| CA 125 (≥ 35 U/mL vs. < 35 U/mL) | 5.45 (1.30–22.56) | 0.019 | 5.90 (1.40–24.32) | 0.014 |
| APOBEC3B (+++/++ vs. ±) | 6.34 (2.80–14.38) | < 0.0001 | 5.18 (2.40–10.80) | < 0.0001 |
| Multivariate analyses | ||||
| FIGO stage (III/IV vs. I/II) | 7.89 (2.33–26.70) | 0.001 | 9.75 (2.89–32.90) | < 0.0001 |
| APOBEC3B (+++/++ vs. ±) | 5.18 (1.40–11.95) | 0.003 | 4.23 (1.60–11.17) | 0.004 |
CA 125 cancer antigen 125, FIGO Federation of Gynecologists and Obstetricians, HR hazard ratio, 95% CI 95% confidence interval